ROTE WILLIAM E.

CIK 00016982621 companySAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001698262

Recent Transactions

50 trades

Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-02-03$32.87/sh−12,446→ 109,087 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2026-01-31+53,570→ 53,570 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-01-31+20,090→ 121,533 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-05-05$21.05/sh−3,198→ 100,241 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2025-05-02−4,920→ 4,920 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-05-02+4,920→ 103,439 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-12$23.53/sh−5,200→ 98,519 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2025-02-10−8,000→ 0 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-10+8,000→ 103,719 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-03$19.78/sh−8,951→ 95,719 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-31+21,500→ 104,670 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2025-01-31+58,000→ 58,000 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-22$19.46/sh−2,437→ 83,170 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-09$11.52/sh−4,387→ 84,455 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-05+6,750→ 88,842 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-02-01$8.53/sh−2,174→ 83,310 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-02-01$8.86/sh−2,590→ 80,720 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2024-01-31+65,000→ 65,000 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-31+25,000→ 85,484 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-23$8.96/sh−2,062→ 60,484 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-09-05$14.71/sh−1,815→ 61,173 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-08-31+3,300→ 62,988 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-05-10$16.59/sh−825→ 59,211 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-02-01$22.25/sh−2,590→ 60,036 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-31+20,250→ 62,626 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2023-01-31+54,500→ 54,500 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2023-01-31+6,750→ 6,750 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-24$21.50/sh−2,062→ 42,376 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-05-11$21.93/sh−750→ 44,485 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-05-11$21.52/sh−813→ 43,672 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2022-01-31+9,840→ 9,840 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-01-31+9,840→ 46,360 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-01-31$27.40/sh−1,125→ 45,235 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2022-01-31+8,000→ 8,000 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2022-01-31+39,360→ 39,360 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-01-24$24.98/sh−1,875→ 36,520 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-01-11$27.40/sh−2,500→ 38,395 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-01-10+5,000→ 40,895 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-08-17$17.12/sh−1,407→ 35,731 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-08-13+4,500→ 37,138 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-05-12$19.46/sh−1,562→ 31,707 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-05-11$19.14/sh−1,563→ 33,269 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-18$28.67/sh−1,250→ 34,832 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-17$27.35/sh−1,250→ 36,082 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-08$31.58/sh−2,250→ 37,332 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-05$31.41/sh−2,250→ 39,582 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-03+4,500→ 41,832 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-03$28.91/sh−2,500→ 38,457 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-03$28.91/sh−1,125→ 37,332 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2021-02-02$30.75/sh−1,125→ 43,457 total

Companies

Travere Therapeutics, Inc.
Chief Research Officer
$TVTX

Recent Filings

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300

SAN DIEGO, CA, 92130

View on SEC.gov